The CheckMate 9LA study was a phase III trial evaluating a novel regimen in 1150 treatment-naïve NSCLC patients without known sensitizing EGFR/ALK genomic tumor aberration. This evidence concerns the gene EGFR and non-small cell lung carcinoma.